Asthma Therapeutics

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability And Reporting Limitations I-1
• Disclaimers I-2
• Data Interpretation & Reporting Level I-2
• Quantitative Techniques & Analytics I-3
• Product Definitions And Scope Of Study I-3
• Inhaled Corticosteroids: I-3
• Beta-2 Adrenoreceptor Agonists I-4
• Combinations I-4
• Anti- leukotrienes I-4
• Others I-4
• Antihistamines I-4
• Methylxanthines I-4
• Mast Cell Stabilizers I-5
• Monoclonal Antibodies I-5
• Anticholinergics I-5

II. EXECUTIVE SUMMARY

1. Market Overview II-1

• Current & Future Analysis II-1
• Competitive Outlook II-1
• Major Asthma Therapeutics by Class II-2
• Facts about Asthma II-2

2. Trends & Issues II-3

• Combination Drugs - Rule the World II-3
• Novel Compounds To Pep Up Growth II-3
• Rise in Pediatric Asthma To Keep Market Lucrative II-3
• Toxic Nature of Asthma Drugs - A Serious Concern II-3
• Life Threatening Drugs Under Regulatory Scan II-3

3. Product Overview II-4

• Causes of Asthma II-4
• Allergens II-4
• Irritants II-4
• Other Factors II-4
• Classes in Asthma II-5
• A. Mild Intermittent Asthma: II-5
• B. Mild Persistent Asthma: II-5
• C. Moderate Persistent Asthma: II-5
• D. Severe Persistent Asthma: II-5
• Asthma Treatments II-6
• Combination Asthma Medications II-6
• Over-the-Counter Asthma Medications II-6
• Immunotherapy (Allergy shots) II-6
• Alternative Therapies II-6
• Asthma Therapeutics II-6
• Corticosteroids II-7
• Beta-2 Adrenoreceptor Agonists II-7
• Mast Cell Stabilizers II-7
• Monoclonal Antibodies II-7
• Immune System: Natural Defenders II-7
• Human Antibodies II-8
• Polyclonal and Monoclonal Antibodies II-8
• Leukotriene Inhibitors II-8
• Methylxanthines: II-8
• Combination Therapeutics: II-8
• Off Label Therapeutics: II-8
• Anticholinergics: II-8
• Antihistamines: II-9
• Asthma Therapeutics by Various Classes II-9

4. Product Launches/Innovations II-10

• Future to Witness A Novel Therapeutic in Asthma Treatment II-10
• Dr. Reddy's Releases Doxobid in India II-10
• Novartis Files Approval for Xolair to Enter Japanese Market II-10
• AstraZeneca Receives Approval for Symbicort II-10
• GSK Alters Labels for Two Asthma Drugs II-10
• DMI BioSciences Starts Evaluating DMI 8393 II-11
• Inflazyme Begins Phase IIb Trial for IPL512,602 II-11
• Neurim Develops A Neuroprotective Compound II-11
• Xolair® Forays into UK II-11
• Critical Therapeutics Rolls Out ZYFLO® II-11
• Ivax Corp. Introduces Qvar EasiBreathe Inhaler II-12
• Altana Rolls Out Respiratory Drug, Alvesco in the UK II-12
• Sepracor Launches XOPENEX HFA II-12
• Polyphor Commences Research for Protease Inhibitors II-12
• Novartis Plans to Apply for A New Drug Approval II-12
• Asmanex Twisthaler 220 mcg Receives US FDA Approval II-12
• GroPep Completes Pre-Clinical Testing of T-Cell Peptide Drug II-13
• Able Laboratories Obtains FDA Approval II-13
• Acceleration Therapeutics' AT-101 Passes Laboratory Test II-13
• Pharmaxis' New Tool to Assess Asthma Passes Clinical Trial II-13
• Aventis Seeks FDA Approval Alvesco® II-13
• Schering-Plough Releases Asmanex Twisthaler II-13
• FDA Clears Xolair to Enter US Market II-14
• Sepracor Completes Phase III Trial for XOPENEX II-14
• Pfizer Conducts Phase II Clinical Studies II-14
• Celera and Bayer Plans to End Collaboration II-14
• Banyu and Kyorin Starts Distribution of Asthma Treatment II-14
• GlaxoSmithKline Introduces Advair II-14
• Novartis Gets FDA Approval for Foradil Aerolizer II-14

5. Recent Industry Activity II-15

• Teva Purchases Ivax II-15
• SkyePharma Strikes A Deal with KOSP II-15
• Ranbaxy Inks an In-Licensing Agreement with Eurodrug II-15
• Pfizer and Rigel Forms A Collaboration II-15
• MAP and Elan Extends Agreement II-15
• Glenmark Collaborates with Teijin Pharma II-16
• Pfizer Acquires Meridica II-16
• Bayer and Apax Forms A New Company II-16
• KOSP Signs Multiple Agreements II-16
• Novartis Pharma Inks A Licensing Agreement with Ivax II-17
• LAB Intends to Purchase Seyvika II-17
• ALTANA and Tanabe Signs A Pact II-17

6. Focus on Select Players II-18

• Abbott Laboratories (US) II-18
• ALTANA Pharma AG (Germany) II-18
• AstraZeneca (UK) II-18
• Boehringer Ingelheim (Germany) II-19
• Genentech, Inc. (US) II-19
• GlaxoSmithKline (UK) II-19
• Merck & Co., Inc. (US) II-19
• Novartis Pharma AG (Switzerland) II-19
• Pfizer Inc. (US) II-20
• Schering-Plough Corporation (US) II-20
• Sepracor Inc. (US) II-20
• The Sanofi-Aventis Group (US) II-21
• 3M (US) II-21

7. Global Market Perspective II-22

• Table 1: World Recent Past, Current and Future Analysis for Asthma Therapeutics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-22
• Table 2: World 10-Year Perspective for Asthma Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-22
• Table 3: World Recent Past, Current and Future Analysis for Inhaled Corticosteroids by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-23
• Table 4: World 10-Year Perspective for Inhaled Corticosteroids by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-23
• Table 5: World Recent Past, Current and Future Analysis for Short Acting Beta Agonists by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-24
• Table 6: World 10-Year Perspective for Short Acting Beta Agonists by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-24
• Table 7: World Recent Past, Current and Future Analysis for Long Acting Beta Agonists by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-25
• Table 8: World 10-Year Perspective for Long Acting Beta Agonists by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-25
• Table 9: World Recent Past, Current and Future Analysis for Combinations by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-26
• Table 10: World 10-Year Perspective for Combinations by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-26
• Table 11: World Recent Past, Current and Future Analysis for Anti-Leukotrienes by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-27
• Table 12: World 10-Year Perspective for Anti-Leukotrienes by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-27
• Table 13: World Recent Past, Current and Future Analysis for Other Asthma Therapeutics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) II-28
• Table 14: World 10-Year Perspective for Other Asthma Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) II-28

III. MARKET

1. The United States III-1

• A. Market Analysis III-1
• Current & Future Analysis III-1
• Asthma Reflections in the US III-1
• Competitive Scenario III-1
• Table 15: Leading Anticholinergic Companies in the US (2006): Percentage Breakdown of Market Share for Boehringer Ingelheim, Dey Inc, Alpharma and Others (includes corresponding Graph/Chart) III-1
• Product Launches/Innovations III-2
• Strategic Developments III-4
• Focus on Key Players III-5
• 3M III-5
• Abbott Laboratories III-5
• Genentech, Inc. III-5
• Merck & Co., Inc. III-6
• Pfizer Inc. III-6
• Schering-Plough Corporation III-6
• Sepracor Inc. III-6
• The Sanofi-Aventis Group III-7
• B. Market Analytics III-8
• Table 16: US Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-8
• Table 17: US 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010(includes corresponding Graph/Chart) III-9

2. Canada III-10

• A. Market Analysis III-10
• Current & Future Analysis III-10
• Product Launches/Innovations III-10
• Strategic Development III-10
• B. Market Analytics III-11
• Table 18: Canadian Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-11
• Table 19: Canadian 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-12

3. Japan III-13

• A. Market Analysis III-13
• Current & Future Analysis III-13
• Product Approvals/Launches III-13
• Strategic Developments III-13
• B. Market Analytics III-14
• Table 20: Japanese Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets IndependentlyAnalyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-14
• Table 21: Japanese 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-15

4. Europe III-16

• Market Analysis III-16
• Current & Future Analysis III-16
• Table 22: European Recent Past, Current and Future Analysis for Asthma Therapeutics by Geographic Region - France, Germany, UK, Italy, Spain and Rest of Europe Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-16
• Table 23: European Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-17
• Table 24: European 10-Year Perspective for Asthma Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain and Rest of Europe for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-18
• Table 25: European 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-19

4a. France III-20

• Market Analysis III-20
• Current & Future Analysis III-20
• Table 26: French Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-20
• Table 27: French 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-21

4b. Germany III-22

• A. Market Analysis III-22
• Current & Future Analysis III-22
• Product Launches/Innovations III-22
• Focus on Key Players III-22
• ALTANA Pharma AG III-22
• Boehringer Ingelheim III-22
• B. Market Analytics III-23
• Table 28: German Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-23
• Table 29: German 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-24

4c. The United Kingdom III-25

• A. Market Analysis III-25
• Current & Future Analysis III-25
• Product Launches/Innovations III-25
• Strategic Developments III-26
• Focus on Key Players III-26
• AstraZeneca III-26
• GlaxoSmithKline III-26
• B. Market Analytics III-27
• Table 30: UK Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-27
• Table 31: UK 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-28

4d. Italy III-29

• Market Analysis III-29
• Current & Future Analysis III-29
• Table 32: Italian Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-29
• Table 33: Italian 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-30

4e. Spain III-31

• Market Analysis III-31
• Current & Future Analysis III-31
• Table 34: Spanish Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-31
• Table 35: Spanish 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-32

4f. Rest of Europe III-33

• A. Market Analysis III-33
• Current & Future Analysis III-33
• Product Approvals/Launches III-33
• Strategic Development III-34
• Focus on Select Player III-34
• Novartis Pharma AG (Switzerland) III-34
• B. Market Analytics III-35
• Table 36: Rest of Europe Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-35
• Table 37: Rest of Europe 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006and 2010 (includes corresponding Graph/Chart) III-36

5. Rest of World III-37

• A. Market Analysis III-37
• Current & Future Analysis III-37
• Product Launches III-37
• Strategic Developments III-37
• B. Market Analytics III-38
• Table 38: Rest of World Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists,Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart) III-38
• Table 39: Rest of World 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart) III-39

IV. COMPETITION

• 1. 3M Company (USA) IV-1
• Table 40: First Quarter Sales Analysis: 2005-2006 (In US$ billion) IV-5
• Table 41: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ billion) IV-5
• Table 42: Annual Sales Analysis: 2004-2005 (In US$ billion) IV-5
• Table 43: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion) IV-5
• Table 44: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-6
• 2. Abbott Laboratories (USA) IV-21
• 3. Able Laboratories, Inc. (USA) IV-30
• 4. Adams Respiratory Therapeutics (USA) IV-31
• Table 45: Annual Sales Analysis: 2004-2006 (In US$ million) IV-31
• Table 46: Annual Sales Analysis by Quarter: 2005-2006 (In US$ million) IV-32
• Table 47: Annual Sales Analysis by Product: 2005-2006 (In US$ million) IV-32
• Table 48: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-32
• 5. Aerovance, Inc. (USA) IV-34
• 6. Almirall Prodesfarma SA (Spain) IV-35
• 7. Alpharma USPD, Inc. (USA) IV-37
• 8. Altana Pharma AG (Germany) IV-38
• Table 49: Annual Sales Analysis: 2004-2005 (In € billion) IV-39
• Table 50: Annual Sales Analysis by Product Segment: 2004-2005 (In € billion) IV-39
• Table 51: Annual Sales Analysis by Geographical Region: 2004-2005 (In € billion) IV-39
• 9. Amgen, Inc. (USA) IV-41
• Table 52: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-42
• Table 53: Annual Sales Analysis: 2004-2005 (In US$ million) IV-42
• Table 54: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-42
• 10. Asthmatx, Inc. (USA) IV-45
• 11. Astrazeneca PLC (UK) IV-46
• Table 55: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ Million) IV-48
• Table 56: Half Yearly Sales Analysis By Quarter: 2005-2006 (H1) (In US$ Million) IV-49
• Table 57: Half Yearly Sales Analysis By Geographic Region: 2005-2006 (H1) (In US$ Million) IV-49
• Table 58: Annual Sales Analysis By Quarter: 2004-2005 (In US$ Million) IV-49
• Table 59: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ Million) IV-49
• Astrazeneca Pharmaceuticals LP (USA) IV-59
• 12. Biocon India Limited (India) IV-63
• Table 60: Annual Sales Analysis: 2004-2005 (In INR million) IV-64
• 13. Boehringer Ingelheim GmbH (Germany) IV-67
• Boehringer Ingelheim Pharmaceuticals, Inc. (USA) IV-71
• Boehringer Ingelheim Ltd. (Canada) IV-71
• 14. Breckenridge Pharmaceutical, Inc. (USA) IV-73
• 15. Cadila Pharmaceuticals Limited (India) IV-74
• 16. Cipla Ltd. (India) IV-77
• 17. Coley Pharmaceutical Group, Inc. (USA) IV-80
• Table 61: Half-Yearly Sales Analysis: 2006-2005 (H1) (In Can$ thousands) IV-80
• Table 62: Quarterly Sales Analysis: 2005-2004 (In Can$ thousands) IV-81
• 18. Cosmobio Co., Ltd. (Japan) IV-82
• 19. Critical Therapeutics, Inc. (USA) IV-84
• Table 63: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-84
• 20. deCODE Genetics (Iceland) IV-86
• Table 64: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-87
• Table 65: Annual Sales Analysis: 2004-2005 (In US$ million) IV-87
• Table 66: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-87
• Table 67: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-87
• 21. DMI BioSciences, Inc. (USA) IV-89
• 22. Dr. Reddy's Laboratories (India) IV-90
• Table 68: First Quarter Sales Analysis: 2005-2006 (Q1) (In INR billion) IV-92
• Table 69: Annual Sales Analysis: 2004-2005 (In INR billion) IV-92
• Table 70: Annual Sales Analysis by Segment: 2004-2005 (In INR billion) IV-93
• Table 71: Annual Sales Analysis by Geographic Region: 2004-2005 (In INR billion) IV-93
• 23. Elan Corporation Plc (Ireland) IV-97
• Table 72: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-98
• Table 73: Annual Sales Analysis: 2004-2005 (In US$ million) IV-98
• Table 74: Annual Sales Analysis By Segment: 2004-2005 (In US$ million) IV-98
• Table 75: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ million) IV-99
• 24. Epitomics, Inc. (USA) IV-101
• 25. Eurodrug Laboratories Group (The Netherlands) IV-103
• 26. Exim Pharm International (India) IV-104
• 27. F. Hoffmann-La Roche Ltd. (Switzerland) IV-106
• Table 76: First Quarter Sales Analysis: 2005-2006 (In CHF billion) IV-107
• Table 77: First Quarter Sales Analysis by Segment: 2005-2006 (In CHF billion) IV-107
• Hoffmann-La Roche, Inc. (USA) IV-110
• Genentech, Inc. (USA) IV-113
• Table 78: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-115
• Table 79: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) (Switzerland)) IV-115
• 28. Forest Laboratories, Inc. (USA) IV-119
• Table 80: First Quarter Sales Analysis: 2006-2007 (In US$ billion) IV-120
• Table 81: Annual Sales Analysis: 2004-2006 (In US$ billion) IV-120
• Table 82: Annual Sales Analysis by Product: 2005-2006 (In US$ billion) IV-120
• Table 83: Annual Sales Analysis by Geographic Region: 2005-2006 (In US$ billion) IV-121
• Table 84: Quarterly Sales Analysis: 2005-2006 (In US$ billion) IV-121
• 29. Gilead Sciences (USA) IV-125
• Table 85: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In USS$ million) IV-126
• Table 86: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In USS$ million) IV-126
• Table 87: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-127
• Table 88: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-127
• 30. Glaxosmithkline PLC (UK) IV-132
• Table 89: Half Yearly Sales Analysis: 2005-2006 (H1) (In £ million) IV-133
• Table 90: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In £ million) IV-133
• Table 91: Annual Sales Analysis by Segment: 2004-2005 (In £ million) IV-133
• Glaxosmithkline (USA) IV-142
• 31. Glenmark Pharmaceuticals Ltd. (India) IV-145
• Glenmark Pharmaceuticals SA (Switzerland) IV-145
• 32. GroPep Limited (Australia) IV-146
• Table 92: Annual Sales Analysis by Business Segment: 2005-2006 (In A$ million) IV-148
• 33. Indoco Remedies (India) IV-150
• 34. Inflazyme Pharmaceuticals Limited (Canada) IV-153
• 35. Janssen-Cilag GmbH (Austria) IV-155
• 36. Kos Pharmaceuticals, Inc. (USA) IV-156
• Table 93: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-157
• Table 94: Annual Sales Analysis: 2004-2005 (In US$ million) IV-157
• 37. Kyorin Pharmaceutical Co., Ltd. (Japan) IV-159
• 38. Lab International, Inc. (Canada) IV-160
• Table 95: Annual Sales Analysis by Business Segment: 2004-2005 (In Can$ million) IV-161
• Table 96: Annual Sales Analysis by Geographic Region: 2004-2005 (In Can$ million) IV-161
• 39. Lark Laboratories (India) IV-164
• 40. MAP Pharmaceuticals, Inc. (USA) IV-166
• 41. Mayne Pharma Pty, Ltd. (Australia) IV-167
• Table 97: Annual Sales Analysis By Segment: 2004-2005 (In A$ Million) IV-167
• Table 98: Annual Sales Analysis By Geographic Region: 2004-2005 (In A$ Million) IV-168
• 42. MediciNova, Inc. (USA) IV-171
• Table 99: Half-Yearly Sales Analysis: 2005-2006 (H1) (In US$ Thousand) IV-171
• 43. Mercia Pharma, Inc. (USA) IV-175
• 44. Merck KGaA (Germany) IV-176
• Table 100: Annual Sales Analysis Segment: 2004-2005 (In € million) IV-178
• Merck & Co., Inc. (USA) IV-182
• Table 101: Half Yearly Sales Analysis By Quarter: 2005-2006 (H1) (In US$ million) IV-183
• Table 102: Half Yearly Sales Analysis by Product: 2005-2006 (H1) (In US$ million) IV-183
• Table 103: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-183
• Table 104: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-184
• Banyu Pharmaceutical Co., Ltd. (Japan) IV-186
• Dey, L.P. (USA) IV-187
• 45. Millennium Pharmaceuticals, Inc. (USA) IV-189
• Table 105: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-189
• Table 106: Quarterly Sales Analysis: 2004-2005 (In US$ million) IV-189
• 46. MorphoSys AG (Germany) IV-192
• Table 107: First Quarter Sales Analysis: 2005-2006 (Q1) (In € million) IV-192
• 47. Neurim Pharmaceuticals (1991) Ltd. (Israel) IV-194
• 48. Nicholas Piramal India Ltd. (India) IV-195
• Table 108: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-196
• 49. Novartis AG (Switzerland) IV-197
• Table 109: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-200
• Table 110: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-201
• Table 111: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-201
• Table 112: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-201
• Novartis Pharma Switzerland AG (Switzerland) IV-209
• Novartis Pharma GmbH (Germany) IV-210
• Sandoz International GmbH (Germany) IV-210
• 50. Oriel Therapeutics, Inc. (USA) IV-212
• 51. Pfizer, Inc. (USA) IV-213
• Table 113: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion) IV-215
• Table 114: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ billion) IV-215
• Table 115: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ billion) IV-216
• Pfizer Consumer Healthcare Division (USA) IV-220
• 52. Pharmaxis Ltd. (Australia) IV-224
• 53. Polyphor Limited (Switzerland) IV-226
• 54. Pure Pharma Limited (India) IV-228
• 55. Ranbaxy Laboratories Ltd. (India) IV-229
• 56. Rigel Pharmaceuticals, Inc. (USA) IV-243
• Table 116: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-243
• Table 117: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-244
• 57. Sanofi-Aventis (France) IV-245
• Table 118: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million) IV-246
• Table 119: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In € million) IV-246
• Table 120: Annual Sales Analysis: 2004-2005 (In € million) IV-246
• Table 121: Annual Sales Analysis by Segment: 2004-2005 (In € million) IV-246
• Table 122: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million) IV-247
• Sanofi-Aventis (USA) IV-252
• 58. Schering-Plough Corporation (USA) IV-254
• Table 123: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-255
• Table 124: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-256
• Table 125: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-256
• Table 126: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-256
• AESCA Pharma GmbH (Austria) IV-260
• 59. Sepracor, Inc. (USA) IV-261
• Table 127: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-261
• Table 128: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-262
• 60. Shinpoong Pharmaceutical Co., Ltd. (South Korea) IV-265
• 61. SkyePharma PLC (UK) IV-266
• Table 129: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In £ million) IV-267
• Table 130: Annual Sales Analysis by Segment: 2004-2005 (In £ million) IV-267
• Table 131: Annual Sales Analysis by Geographic Region: 2004-2005 (In £ million) IV-268
• 62. Sumit Laboratories (India) IV-271
• 63. Surya Pharmaceutical Ltd. (India) IV-272
• 64. Synairgen Research Limited (UK) IV-272
• 65. Tanabe Seiyaku Co., Ltd. (Japan) IV-273
• Table 132: First Quarter Sales Analysis: 2006-2007 (Q1) (In US$ million) IV-273
• Table 133: First Quarter Sales Analysis by Business Segment: 2005-2006 (Q1) (In Yen million) IV-274
• Table 134: Annual Sales Analysis: 2005-2006 (In US$ million) IV-274
• Table 135: Annual Sales Analysis by Business Segment: 2004-2005 (In Yen million) IV-274
• 66. TEVA Pharmaceutical Industries Ltd. (Israel) IV-277
• Table 136: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-278
• Table 137: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-278
• IVAX Corporation (USA) IV-287
• Table 138: Nine Months Sales Analysis: 2004-2005 (Nine Months Ended, September) (In US$ billion) IV-289
• Table 139: Quarterly Sales Analysis: 2004-2005 (Nine Months Ended, September) (In US$ billion) IV-289
• Table 140: Nine Months Sales Analysis by Product Category: 2004-2005 (Nine Months Ended, September) (In US$ billion) IV-289
• Table 141: Nine Months Sales Analysis by Geographical Region: 2004-2005 (Nine Months Ended, September) (In US$ billion)Limited (Israel)) IV-290
• Ivax Laboratories, Inc. (USA) IV-295
• 67. Trudell Medical International (Canada) IV-296
• 68. UCB SA (Belgium) IV-297
• Table 142: Annual Sales Analysis: 2004-2005 (In € million) IV-297
• Table 143: Annual Sales Analysis By Business Segment: 2004-2005 (In € million) IV-297
• 69. Zedawn Formulations (P) Ltd. (India) IV-300
• 70. Zenyth Therapeutics Limited (Australia) IV-301
• Table 144: Annual Sales Analysis: 2004-2005 (In A$ million) IV-301